Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to determine whether dutasteride may influence the expression of angiogenesis factors such as hypoxia inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF) in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Collaborators: GlaxoSmithKline; The Korean Urological Association
• Treatments: Dutasteride

Criteria

Inclusion Criteria:

• informed consent

• 50 years old or older

• International Prostate Symptom Score (IPSS) >8

• Maximum flow rate (Qmax) <15 ml/s

• transurethral resection of the prostate (TURP)

Exclusion Criteria:

• urethral catheter

• urinary tract infection (UTI)

• liver disease

• renal disease

• unexplained hematuria

• prostate specific antigen (PSA) > 4ng/ml (included if prostate biopsy was negative)

• interstitial cystitis

• bladder cancer or prostate cancer

• pelvic surgery or irradiation